PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF SERIES B CONVERTIBLE PREFERRED STOCK OFFERING

Core Viewpoint - PetVivo Holdings, Inc. has secured $5 million in equity financing through a Subscription Agreement, which will support the commercialization of its innovative veterinary medical products [1][4]. Group 1: Financing Details - The company has entered into a Subscription Agreement for $5 million in exchange for five million shares of Series B Convertible Preferred Stock [1]. - The initial proceeds of $600,000 were received on March 26, 2025, with the remaining $4.4 million expected within the next sixty days [1]. Group 2: Product Overview - The funds will be used to advance the commercialization of Spryng with OsteoCushion Technology and PrecisePRP [2][4]. - Spryng is an intra-articular injectable device that integrates with the animal's subsynovial tissue to manage joint pain and conditions like osteoarthritis [2]. - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for easy use by veterinarians, providing a consistent dose of 4 billion platelets per vial [3]. Group 3: Company Strategy and Market Position - PetVivo focuses on leveraging human therapies for companion animals, aiming for a quicker market entry compared to pharmaceuticals [7]. - The company holds a portfolio of twenty-one patents protecting its biomaterials and products, indicating a strong intellectual property position [8].